The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Thyroid Cancer Drugs Market Become By 2030 Compared To 2026?
The thyroid cancer drugs market has seen rapid expansion in recent years. Its valuation is expected to rise from $1.32 billion in 2025 to $1.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.8%. This historical growth can be attributed to an increasing incidence of thyroid cancer, the adoption of kinase inhibitors, enhancements in cancer diagnostics, the expansion of oncology hospitals, and improved access to targeted therapies.
The thyroid cancer drugs market size is set to experience rapid expansion in the upcoming years. It is forecast to reach $2.39 billion in 2030, progressing at a compound annual growth rate (CAGR) of 12.8%. This growth over the forecast period is primarily driven by the increasing development of personalized oncology drugs, the rising prevalence of advanced thyroid cancer cases, heightened clinical trial activities, the wider application of immunotherapy combinations, and elevated spending in oncology healthcare. Significant trends anticipated during this period include a greater embrace of targeted multikinase therapies, an escalation in the use of combination drug regimens, an intensified focus on advanced and refractory thyroid cancer, the expansion of precision oncology treatment strategies, and improved hospital-based management of thyroid cancer.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp
Which Growth Factors Are Strengthening The Thyroid Cancer Drugs Market Landscape?
The thyroid cancer drugs market is set for growth primarily due to the increasing frequency of thyroid cancer cases. This condition involves the development of malignant tumors within the thyroid gland, necessitating prompt diagnosis and effective therapeutic interventions to prevent disease progression and metastasis. The rise in thyroid cancer incidences is attributed to a combination of enhanced detection through more sensitive diagnostic procedures and increased exposure to environmental factors. This growing prevalence of thyroid cancer supports the thyroid cancer drugs sector by boosting demand for specific treatments such as targeted therapies, immunotherapies, radiopharmaceuticals, and hormone-suppressing medications, which collectively improve patient outcomes and long-term survival. For instance, in September 2025, Cancer Research United Kingdom, a UK-based non-profit organization focused on cancer research and patient support, estimated approximately 6,600 new cases of thyroid cancer annually by 2038-2040. They further projected that incidence rates are expected to increase by 27%, from around 7.3 cases per 100,000 people per year in 2024-2026 to about 9.2 cases per 100,000. Therefore, the escalating incidences of thyroid cancer are a significant driver for the expansion of the thyroid cancer drugs market.
How Is The Thyroid Cancer Drugs Market Distributed Across Key Segments?
The thyroid cancer drugs market covered in this report is segmented –
1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users
Subsegments:
1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab
2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib
3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib
4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin
5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib
6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab
7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib
8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab
Which Trends Are Supporting The Evolution Of The Thyroid Cancer Drugs Market?
Leading firms within the thyroid cancer market are developing novel products like selpercatinib, aiming to enhance therapeutic choices and patient results. Selpercatinib, known commercially as Retevmo, serves as a drug for addressing multiple cancers linked to Rearranged During Transfection (RET) mutations, encompassing advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For example, in September 2024, the US-based pharmaceutical entity, Eli Lilly and Company, secured approval for selpercatinib (Retevmo) from the Food and Drug Administration (FDA), a US federal agency dedicated to public health protection, for treating advanced or metastatic medullary thyroid cancer (MTC) that carries a RET mutation. This authorization extends to both adult and pediatric individuals aged 2 years and older who need systemic therapeutic intervention. This recent conventional approval signifies a notable progression in the therapeutic options available for patients afflicted with this particular form of thyroid cancer.
Who Are The Businesses Driving Activity In The Thyroid Cancer Drugs Market?
Major companies operating in the thyroid cancer drugs market are AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH
Access The Complete Thyroid Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report
Which Region Holds The Largest Share In The Thyroid Cancer Drugs Market?
North America was the largest region in the thyroid cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Thyroid Cancer Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp
Browse Through More Reports Similar to the Global Thyroid Cancer Drugs Market 2026, By The Business Research Company
Thyroid Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report
Anti Thyroid Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report
Breast Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model